MS treatment

Multiple Sclerosis

Multiple Sclerosis (MS) research is a long-standing focus area at the University of Calgary, where basic and clinical researchers support a cyclical process of discovery and translation, contributing to new treatments for patients. The team is led by Drs. V. Wee Yong and Sarah Morrow and includes researchers who have published more than 90 peer-reviewed articles in the past year. A landmark success for this group was the discovery that minocycline, a common acne medication, can slow the progress of relapsing-remitting MS, a discovery the team carried from bench to the completion of a Phase III trial. These findings were published in the New England Journal of Medicine in 2017. The team holds a Brain and Mental Health Strategic Research Fund grant, focusing on developing innovative animal models.


MS team leaders:
Dr. V. Wee Yong and Dr. Sarah Morrow

MS team contact:


MS program manager: 
Dr. Trisha Lichtenberger